HAWK vs RAPP
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
HAWK · HawkEye 360$14.79 ▲ 15.91%
RAPP · Rapport Therapeutics$24.44 ▲ 3.04%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- HAWK -56.5%
- RAPP -38.8%
Head to head
| Metric | HAWK | RAPP |
|---|---|---|
| Price | $14.79 | $24.44 |
| Change today | ▲ 15.91% | ▲ 3.04% |
| Market cap | $1.45B | $1.45B |
| Return, 3 months | -41.3% | -48.0% |
| Return, year to date | – | -19.4% |
| Return, 1 year | – | -4.8% |
| P/E (TTM) | -113.8 | -7.7 |
| P/B | 1.8 | 3.7 |
| P/E percentile vs own 5y | 60th | 73rd |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | +87.1% | – |
| Net profit growth (YoY) | -1,048.4% | -111.8% |
| Gross margin | 50.2% | – |
| Operating margin | -15.5% | -767.6% |
| Net margin | -10.1% | -685.8% |
| Return on equity | -2.9% | -40.0% |
| Analyst target vs. price | +71.9% | +184.0% |
| Analyst buy share | 100% | 100% |
| RSI (14) | 56 | 38 |
| 30-day volatility | 73.9% | 95.7% |
| Max drawdown, 1 year | -66.3% | -57.1% |
| Trend read | Strong uptrend | Strong downtrend |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- HAWK is the largest of the group by market value.
- HAWK carries the lowest trailing P/E.
- HAWK keeps the most profit per dollar of sales.
- HAWK has been the calmest stock over the last 30 days.